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further outgrowth (a property referred to as
distalization).
Kragl et al. (2009) use their fluorescently
labeled axolotl to ask whether two line-
ages, cartilage, and Schwann cells, re-
member their PD level of origin after trans-
plant into unlabeled hosts. When they
grafted GFP-labeled cartilage from prox-
imal levels of the upper arm onto unla-
beled upper arms and then amputate
through the graft, they find that donor-
derived labeled cells contribute to the
entire length of the regenerate distal of
the amputation plane. That the upper-
arm cartilage cells can contribute to the
distal lower-arm regenerate illustrates
the property of distilization discussed
above. In contrast, when distal cartilage
of the finger tips are grafted into the upper
arm then amputated through the graft,
cells from the distal cartilage are generally
excluded from the proximal regenerate
and are found instead in the cartilages of
the hand. These experiments reveal that
the cartilage lineage retains and acts on
positional memory when passed through
the blastema.
Other lineages need not retain their
positional memories during regeneration.
To explore this, Kragl et al. (2009) trans-
planted GFP-labeled Schwann cells from
hands into upper arms and then ampu-
tated through the graft. Rather than
homing to the hand regenerate, labeled
Schwann cells were found throughout
the PD axis of the regenerated limb.
These results indicate that unlike carti-
lage, the Schwann cell does not retain or
act on memory of its position but rather
can acquire new positions. The findings
now raise the question of which other line-
ages in the limb retain and act on PD posi-
tional memory when passed through the
regeneration blastema.
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Nutrient overabundance is known to promote cellular hypertrophy, a significant pathological event in
diseases like diabetes and cancer, although mechanisms have remained unclear. In this issue of Develop-
mental Cell, Wu and Derynck provide a new model that links metabolism and cell growth by demonstrating
that hyperglycemia can increase TGF-b-dependent activation of the mTOR pathway to promote cellular
hyperplasia.Control of cell size is a central feature of
tissue homeostasis. If cells atrophy, cell
metabolism decreases, and cell size and
growth potential are reduced (Rathmell
et al., 2000). Conversely, cellular hyper-
trophy is associated with increased
metabolism, which can lead to inflamma-
tion, reduced cellular or tissue function,
and pathologies like diabetes, obesity,
and cancer (Conlon and Raff, 1999). Cell
hypertrophy represents an increase in cell
size through elevated protein synthesis
without DNA duplication and can be
induced by growth factors, hormones,6 Developmental Cell 17, July 21, 2009 ª200extracellular matrix protein accumulation,
and hyperglycemia. The phosphatidylino-
sitol-3 kinase (PI3K)/mTOR pathway has
been genetically and biochemically shown
to regulate cell size (Plas and Thompson,
2005). Activation of this pathwaypromotes
cell growth, while inhibition prevents
hypertrophy and can often lead to cellular
atrophy.
Whilemechanisms that control thePI3K/
mTOR pathway in growth-factor-stimu-
lated hypertrophy have been well defined,
the mechanisms by which hyperglycemia
(elevated glucose levels) promotes hyper-9 Elsevier Inc.trophy are unclear (Wolf and Ziyadeh,
1999). A manuscript by Wu and Derynck
(2009) in this issue of Developmental Cell
now highlights a vital contribution by
transforming growth factor beta (TGF-b)
to this process, identifying a role for TGF-b
in glucose-induced hypertrophy through
activation of matrix metalloproteinases
(MMPs) and the Akt/mTOR pathway. This
novel connection between glucose over-
abundance and cellular pathology may
provide new directions in understanding
both control of cell growth and the spec-
trum of pathologies that characterize the
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PreviewsFigure 1. Model of Glucose-Stimulated Cellular Hypertrophy
Hyperglycemia increases TGF-b signaling through two proposed mechanisms (red dashed arrows).
Glucose overabundance led to increased cell surface levels of TbRI and RII as well as activation and pro-
cessing of latent TGF-b by MMP-2 and MMP-9. Cellular hypertrophy is caused by Smad-independent
activation of the PI3K/Akt/mTOR pathway.metabolic syndrome that is associated
with obesity.
TGF-b functions as a pleiotropic cyto-
kine that either suppresses or promotes
cell growth and proliferation. In healthy
tissues, TGF-b acts as an inhibitory cyto-
kine, but during tumorigenesis TGF-b
promotes tumor growth, a flip in function
described as the TGF-b paradox. The
outcome of TGF-b-induced signaling is,
therefore, context dependent. How this
switch occurs is poorly understood, but
the fact that the TGF-b receptor can
initiate multiple signaling pathways may
contribute. TGF-b activation leads to
phosphorylation and activation of Smad
transcription factors, which can directly
control target gene expression. In addi-
tion, however, TGF-b has Smad-indepen-
dent effects, such as activation of the
PI3K/mTOR pathway (Lamouille and Der-
ynck, 2007). The finding that both hyper-
glycemia and TGF-b can promote hyper-
trophy of epithelial cells (Ziyadeh, 2004)
led Wu and Derynck to test a possible
role for TGF-b and PI3K/mTOR in medi-
ating glucose-stimulated hypertrophy.
In support of this hypothesis, Wu and
Derynck show that blocking the activity
of TGF-b receptor I (TbRI) kinase by phar-macological or genetic means prevented
glucose-induced hypertrophy. Cells cul-
tured in high levels of glucose, represen-
tative of uncontrolled hyperglycemia in
diabetes, exhibited elevated levels of
TGF-b signaling. Glucose increased both
Smad-dependent signaling and Smad-
independent activation of the PI3K/Akt/
mTOR pathway. The latter pathway was
critical for glucose-induced hypertrophy
because the mTOR inhibitor rapamycin
prevented cell growth. These data sug-
gest that TGF-b and TbRI mediate the
response to glucose via the activation of
the PI3K/Akt/mTOR pathway.
How does high glucose elicit activation
of the TGF-b pathway? Nutrient-sensing
signaling mechanisms can affect cells in
anumberofways, and theauthorsdemon-
strate that hyperglycemia activated TGF-b
signaling at the levels of both receptor and
ligand availability (Figure 1). Although high
levels of glucose did not increase the total
cellular expression of TGF-b receptors,
trafficking (recycling of TGF-b receptors
to the cell surface) was selectively in-
creased. A different cell surface receptor,
the transferrin receptor, was not affected
by changes in glucose. In addition to the
TGF-b receptors, increased glucose avail-Developmentalability also promoted MMP-2/9-depen-
dent processing and activation of the
TGF-b ligand.
Each of these processes may be critical
for linking cellular nutrient status with cell
signaling. Several key mechanistic ques-
tions remain, however. One critical issue
is whether glucose must be metabolized
to elicit TGF-b-dependent cell hyper-
trophy. Hyperglycemia can directly alter
glucose metabolism, as well as cause
changes in lipid metabolism and protein
glycosylation or oxidation. With these
multifaceted effects of highglucose levels,
it will be important to establish specific
metabolic pathways and metabolites that
may mediate the impact on TGF-b and
hypertrophy.
Downstream of glucose or glucose
metabolism, the primary causes of the
increased trafficking of TGF-b receptors
and of processing of TGF-b ligand to an
active form by MMP-2 and MMP-9 also
remain unclear. The TGF-b receptor may
be selectively modified. It may associate
with distinct proteins in hyperglycemia,
or, possibly, more general changes in
Rab proteins or lipid microdomains may
occur and selectively impact TbRI at high
levels of glucose. In either case, it will be
interesting in future work to determine if
other cell surface receptors are also
affected by hyperglycemia—a prospect
that could have significant implications
for the pathology of diabetes and the
metabolic syndrome. Regulation of
MMP-2/9 can occur through altering
MMP expression or inhibiting MMP inhib-
itory enzymes known as tissue inhibitors
of metalloproteinases (TIMP). The activity
of MMPs depends on the ratio between
MMPsand TIMPs, and high glucose levels
may alter this ratio (Tarallo et al., 2009).
How MMPs and TIMPs are regulated by
nutrient availability or metabolism,
however, remains largely uncertain.
Activation of the Akt/mTOR signaling
pathway by TbRI and Smad-independent
signaling ultimately leads to a glucose-
induced increase in cell size and hyper-
trophy. This pathway plays a well-
established role in glucose uptake and
consumption by both normal and can-
cerous cells (Plas and Thompson, 2005).
This reciprocal control between glucose
metabolism and Akt/mTOR suggests
that additional feedback mechanisms
may exist in glucose-driven cell hyper-
trophy. Given the contradictory roles ofCell 17, July 21, 2009 ª2009 Elsevier Inc. 7
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moting cell proliferation (Rahimi and
Leof, 2007), such feedback mechanisms
may play roles in TGF-b-induced hyper-
trophy. Similarly, pathways that impinge
on TGF-b or Akt signaling may be impor-
tant modulators of glucose-induced hy-
pertrophy.
In a global context, these findings
suggest that glucose overavailability can
have significant and direct effects on
important cell signaling pathways. In
addition to signaling pancreatic b-cells
to secrete insulin, hyperglycemia can
lead to inflammation and Toll-like receptor
signaling (Shi et al., 2006), and elevated
glucose can inhibit apoptosis (Plas and
Thompson, 2005). With the rapidly in-
creasing obesity and diabetes epidemics,
understanding how cells respond to8 Developmental Cell 17, July 21, 2009 ª200changes in glucose availability, for
instance during hyperglycemia, is critical.
Cellular hypertrophy can promote a
variety of pathologies. Glucose-stimu-
lated hypertrophy via activation of TGF-b
and the PI3K/Akt/mTOR pathway thus
provides another example of nutrient
sensing and signaling that is clinically
important and may impact a variety of
other cellular physiologies throughMMPs,
TGF-b, and the Akt/mTOR pathway.
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